The patients’ clinical, demographic, and laboratory data also were reviewed. The continuous attenuation parameter (CAP) and liver stiffness measurement (LSM) evaluated with vibration-controlled ...

The 19th reports that for those living with HIV, extreme weather events make it more difficult to stay on top of medications. In separate climate news, rising temperatures may propel a wider spread of ...

William Blair has the equivalent of a buy rating on the stock, as do all 13 analysts offering coverage of the stock on FactSet. The bank is one of many expecting Viking to be a takeover target, given ...

The GLP-1 receptor agonist improved both histology and fibrosis in patients, with additional improvements in their liver ...

Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel ...

Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH ...

Patients in the treatment arms received 1 mg, 2.5 mg, 5 mg or 10 mg doses. After 52 weeks of treatment, patients taking the ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

A study led by scientists at Massachusetts General Hospital has found that growth hormone could help improve liver health in ...

Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led ...

The response rate in this study -- the proportion of patients experiencing reduction in liver fat ≥30% -- ranged from 64% to ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...